Prior Authorization Requirement Updates

Service Description	Procedure Code	Procedure Code Description	Effective Date	Prior Authorization Rule
Laboratory Services	0631U	Oncology (solid tumor), DNA, sequence analysis of 15 genes including BRCA1 and BRCA2 for identification of clonal hematopoiesis, blood, reported as tumor-derived or nontumor-derived	7/1/2026	Yes
Laboratory Services	0632U	Red blood cell antigen (fetal RhD gene analysis), multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), plasma from pregnant individuals known to be RhD negative, reported as detected or not d	7/1/2026	Yes
Laboratory Services	0633U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA (cfDNA), next-generation sequencing (NGS) analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants and to determine fetal inherit	7/1/2026	Yes
Laboratory Services	0634U	Oncology (breast cancer), cell-free DNA (cfDNA), evaluation of 11 ESR1 variants (E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G, V422del, L536H, L536P, Y537D) using droplet digital PCR (ddPCR), plasma, reported as positive or negative	7/1/2026	Yes
Laboratory Services	0635U	Autoimmune (atopic dermatitis), mRNA, next-generation sequencing (NGS), gene expression profiling of 487 genes, noninvasive skin-surface scraping, algorithm reported as likelihood of response to therapy	7/1/2026	Yes
Laboratory Services	0636U	Babesia (Babesiosis), antibody detection of 20 recombinant protein groups, by immunoassay, IgG	7/1/2026	Yes
Laboratory Services	0637U	Babesia (Babesiosis), antibody detection of 20 recombinant protein groups, by immunoassay, IgM	7/1/2026	Yes
Laboratory Services	0638U	Bartonella (Bartonellosis), antibody detection of 32 recombinant protein groups, by immunoassay, IgG	7/1/2026	Yes
Laboratory Services	0639U	Bartonella (Bartonellosis), antibody detection of 32 recombinant protein groups, by immunoassay, IgM	7/1/2026	Yes
Laboratory Services	0640U	Oncology (leptomeningeal metastases), tumor cell selection, identification, detection and enumeration based on differential CD318(CDCP1), SUSD2, CD340(erbB2/HER2), HGFR/cMET, FOLR1, EGFR, N cadherin, MUC1, EpCAM, and TROP2 antibody biomarkers, cerebrospin	7/1/2026	Yes
Laboratory Services	0641U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), using formalin-fixed paraffin-embedded (FFPE) tissue and blood samples, initial (baseline) assessment	7/1/2026	Yes
Laboratory Services	0642U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), whole blood, comparison to previously performed analyses, reported as trend in circulating tumor DNA (ctDNA) level	7/1/2026	Yes
Laboratory Services	0643U	Oncology (genitourinary cancer), cell-free circulating tumor DNA (ctDNA), 200 genes, next-generation sequencing (NGS), interrogation for single-nucleotide variants (SNVs), insertions/deletions, gene rearrangements, copy number alterations, and tumor mutat	7/1/2026	Yes
Laboratory Services	0644U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, blood or bone marrow, personalized assay design and baseline quantification	7/1/2026	Yes
Laboratory Services	0645U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, based on digital PCR, blood or bone marrow, reported as not detected or detected with estimated abundance	7/1/2026	Yes
Laboratory Services	0646U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA, whole blood, and formalin-fixed paraffin-embedded (FFPE) tumor tissue DNA, baseline assessment	7/1/2026	Yes
Laboratory Services	0647U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA (cfDNA), whole blood, assessment utilizing patient-specific tumor information, reported as negative or percent circulating tumor DNA (ctDNA)	7/1/2026	Yes
Laboratory Services	0648U	Oncology (solid tumor), targeted genomic sequencing analysis, to detect deletions, insertions, and substitutions in 42 genes, copy number amplifications in 10 genes, and fusions and splice variants in 18 driver genes from DNA and RNA extracted from formal	7/1/2026	Yes

Laboratory Services	0649U	Neurology (Alzheimer disease), DNA, targeted next-generation sequencing (NGS) of AD-1 and AD-2 target regions, whole blood, prognostic algorithmic analysis, reported as categorization of cognitive status	7/1/2026	Yes
Laboratory Services	0650U	Drug metabolism (adverse drug reactions and drug response), genotyping of 9 genes (ie, CYP2D6, CYP2C19, G6PD, SLCO1B1, HLA-B*58:01, NAT2, CYP2C9, VKORC1, ABCG2), reported as metabolizer status and transporter function	7/1/2026	Yes
Laboratory Services	0651U	Oncology (hereditary cancer), genomic DNA, 55 hereditary cancer pre-dispositioned genes, next-generation sequencing (NGS) and digital multiplex ligation-dependent probe amplification for variants, small indels (<40 base pairs), using saliva, whole blood o	7/1/2026	Yes
Laboratory Services	0652U	Drug metabolism (adverse drug reactions), DNA analysis of 13 genes by targeted genotyping, using saliva or buccal swab, reported as diplotype and metabolizer status	7/1/2026	Yes
Laboratory Services	0653U	Nephrology (inherited kidney disorders), DNA, analysis of approximately 700 genes associated with inherited kidney diseases by exome sequencing, using whole blood, saliva, or nail clipping, reported as an interpretive clinical report classifying pathogeni	7/1/2026	Yes
Laboratory Services	0654U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by western blot analysis, using cultured skin fibroblasts, diagnostic qualitative result	7/1/2026	Yes
Laboratory Services	0655U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by spectrophotometric kinetic assay, using cultured skin fibroblasts, diagnostic quantitative result	7/1/2026	Yes
Laboratory Services	0656U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by radioactive activity assay, using cultured skin fibroblasts, diagnostic quantitative result	7/1/2026	Yes
Laboratory Services	0657U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of comparator nuclear and mitochondrial DNA by next-generation sequencing (NGS), using blood or buccal sample, relevant variants reported with proband results	7/1/2026	Yes
Laboratory Services	0658U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single-nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparental di	7/1/2026	Yes
Laboratory Services	0659U	Rare diseases (constitutional/heritable disorders), ultrarapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single-nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparent	7/1/2026	Yes
Category III	1026T	Transvaginal laser photobiomodulation therapy of pelvis, provided by a physician or other qualified health care professional	7/1/2026	Yes
Category III	1027T	Percutaneous insertion or replacement of neurostimulation catheter via left subclavian or left jugular vein into the superior vena cava, with verification of capture of phrenic nerves, mapping and programming, and delivery of transvenous phrenic neurostim	7/1/2026	Yes
Category III	1028T	Mapping and programming of neurostimulation catheter with delivery of transvenous phrenic neurostimulation therapy in ventilated patients, with repositioning and verification of left phrenic nerve capture, per session	7/1/2026	No
Category III	1029T	Mapping and programming of neurostimulation catheter with delivery of transvenous phrenic neurostimulation therapy in ventilated patients, without catheter repositioning, per session	7/1/2026	No
Category III	1030T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]), cumulative time for up to 30 days; initial 30 minutes	7/1/2026	Yes
Category III	1031T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]), cumulative time for up to 30 days; each additional 30 minutes (List separately in addition to code for primary procedure)	7/1/2026	No

Category III	1032T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]) and digital simulation, cumulative time for up to 30 days; initial 60 minutes	7/1/2026	Yes
Category III	1033T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]) and digital simulation, cumulative time for up to 30 days; each additional 30 minutes (List separately in addition to code for prima	7/1/2026	No
Category III	1034T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]), digital simulation, and computational analyses (eg, computational fluid dynamics, finite element analysis), cumulative time for up	7/1/2026	Yes
Category III	1035T	Creation of digital 3D model from surface mesh files of patient-specific anatomy (eg, final anatomic representation [FAR]), digital simulation, and computational analyses (eg, computational fluid dynamics, finite element analysis), cumulative time for up	7/1/2026	Yes
Category III	1036T	Noninvasive hemodynamic assessment with pulmonary pressures and ejection fraction when performed, including passive acquisition of acoustic and electrical signals, augmentative algorithmic analysis, and generation of a clinical report with review, interpr	7/1/2026	No
Category III	1037T	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant pancreatic tissue, including imaging guidance	7/1/2026	Yes
Category III	1038T	Autologous muscle cell therapy, injection(s) of muscle progenitor cells into the tongue, including esophagoscopy, when performed	7/1/2026	Yes
Category III	1039T	Connectomic analysis of previously performed multi-modal brain magnetic resonance imaging (MRI) requiring physician or other qualified health care professional (QHP) analysis of software- and physician-generated structural and functional maps for integrat	7/1/2026	Yes
Category III	1040T	Bronchoscopy, flexible, with bronchial cryotherapy, 1 lung, including trachea, when performed	7/1/2026	No
Category III	1041T	Augmentative algorithmic analysis of encephalographic waveforms to identify the source and propagation of epileptiform activity, including artifact reduction with analysis of 3D localization of spike sources throughout the examination, 3D animations over	7/1/2026	Yes
Category III	1042T	Implantation of absorbable urologic scaffold for prostatic urethra restoration of reconstructed bladder neck and urethral anastomosis (List separately in addition to code for primary procedure)	7/1/2026	No
Category III	1043T	Quantitative magnetic resonance, without imaging, for analysis of liver tissue, including assessment of 1 or more parameters (eg, proton density fat fraction [PDFF], water diffusion, T1-water relaxation time), with automatically generated report	7/1/2026	Yes
Category III	1044T	Harvest of full-thickness skin for autologous heterogeneous skin-construct graft, including direct closure of donor site; first 5 sq cm or less	7/1/2026	No
Category III	1045T	Harvest of full-thickness skin for autologous heterogeneous skin-construct graft, including direct closure of donor site; each additional 5 sq cm, or part thereof (List separately in addition to code for primary procedure)	7/1/2026	No
Category III	1046T	Autologous heterogeneous skin-construct graft application, trunk, arms, legs; first 50 sq cm or less, or 0.5% of body area of infants and children	7/1/2026	Yes
Category III	1047T	Autologous heterogeneous skin-construct graft application, trunk, arms, legs; each additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	7/1/2026	No
Category III	1048T	Autologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 50 sq cm or less, or 0.5% of body area of infants and children	7/1/2026	Yes

Prior Authorization Requirement Updates

Category III	1049T	Autologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part the	7/1/2026	No
Category III	1050T	Insertion, subcutaneous heart failure decompensation monitor, containing sensors that measure, at a minimum, heart rate, impedance, respiration rate, physical activity, heart sounds	7/1/2026	Yes
Category III	1051T	Removal of subcutaneous heart failure decompensation monitor	7/1/2026	No
Category III	1052T	Interrogation device evaluation(s), (in person or remote) up to 30 days, insertable subcutaneous heart failure decompensation monitor, analysis of physiologic parameters, including, at a minimum, heart rate, impedance, respiration rate, physical activity,	7/1/2026	No
Category III	1053T	Programming device evaluation (in person or remote) of subcutaneous heart failure decompensation monitor, with analysis of physiologic parameters, including, at a minimum, heart rate, impedance, respiration rate, physical activity, heart sounds, with gene	7/1/2026	No
Pathology and Laboratory Services	87638	Infectious agent detection by nucleic acid (DNA or RNA); rubeola (measles) virus	5/15/2026	No
Injectable Drugs	A9574	Injection, ferumoxytol, 1 mg	7/1/2026	No
Medical/Surgical Supplies and Devices-Other Implants	C1609	Vertebral device, motion-preserving, with screw fixation	7/1/2026	No
Medical/Surgical Supplies and Devices-Other Implants	C8014	Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, including use of a suction enabled ureteral access sheath, with irrigation (if performed)	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0574	Management of new patient with dementia residing in an eligible residential care community, for use only in a Medicare-approved CMMI model (services must be furnished within a patient's eligible residential care community, including assisted living facili	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0575	Management of established patient with dementia residing in an eligible residential care community, for use only in a Medicare-approved CMMI model (services must be furnished within a patient's eligible residential care community, including assisted livin	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0669	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of early cardio-kidney-metabolic (ECKM) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); initial 12-month	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0670	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of early cardio-kidney-metabolic (ECKM) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); follow-on 12-mont	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0671	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of cardio-kidney-metabolic (CKM) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); initial 12-month p	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0672	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of cardio-kidney-metabolic (CKM) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); follow-on 12-month	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0673	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of musculoskeletal (MSK) conditions (chronic musculoskeletal pain); initial 12-month treatment period, per month	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0674	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of behavioral health (BH) conditions (one or more of: depression, anxiety); initial 12-month period, per month	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0675	Outcome-Aligned Payment (OAP) for technology-enabled chronic care management of behavioral health (BH) conditions (one or more of: depression, anxiety); follow-on 12-month period, per month	7/1/2026	No

Miscellaneous Services, Procedures, and Reports	G0676	Standard comanagement service payment for documented review of clinical updates from ACCESS participant managing cardio-kidney-metabolic conditions (early cardio-kidney-metabolic [ECKM] or cardio-kidney-metabolic [CKM] track), per review	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0677	Standard comanagement service payment for documented review of clinical updates from ACCESS participant managing musculoskeletal (MSK) conditions, per review	7/1/2026	No
Miscellaneous Services, Procedures, and Reports	G0678	Standard co-management service payment for documented review of clinical updates from ACCESS participant managing behavioral health (BH) conditions (depression, anxiety), per review	7/1/2026	No
Immunization-Medicine	90616	Influenza virus vaccine, trivalent (tIRV), mRNA, 37.5 mcg/0.38 mL dosage, for intramuscular use	7/1/2026	No
ImmuNoizatioNo-MediciNoe	90639	INoflueNoza virus vacciNoe, quadrivaleNot (qIRV), mRNoA; 50 mcg/0.5 mL dosage, for iNotramuscular use	7/1/2026	No
Injectable Drugs	C9310	Injection, leucovorin calcium (Avyxa), 1 mg	7/1/2026	N
Injectable Drugs	J0528	Injection, fosfomycin disodium, 20 mg	7/1/2026	Yes
Injectable Drugs	J1289	Injection, narsoplimab-wuug, 1 mg	7/1/2026	Yes
Injectable Drugs	J1577	Injection, immune globulin (Qivigy), 100 mg	7/1/2026	Yes
Injectable Drugs	J2361	Injection, depemokimab-ulaa, 1 mg	7/1/2026	Yes
Pharmacy Drugs-Prescription	J2374	Apraclonidine HCl ophthalmic, 1% solution, 0.1 ml	7/1/2026	Yes
Pharmacy Drugs-Prescription	J2789	Riboflavin 5'-phosphate, ophthalmic solution (Epioxa HD/Epioxa), up to 2 ml	7/1/2026	Yes
Injectable Drugs	J3386	Injection, etuvetidigene autotemcel, per treatment	7/1/2026	Yes
Injectable Drugs	J3405	Injection, onasemnogene abeparvovec-brve, per treatment	7/1/2026	Yes
Injectable Drugs	J7176	Injection, human fibrinogen-chmt (Fesilty), 1 mg	7/1/2026	Yes
Injectable Drugs	J9053	Injection, belantamab mafodotin-blmf, 0.1 mg	7/1/2026	N-PA19
Injectable Drugs	J9062	Injection, amivantamab 5 mg and hyaluronidase-lpuj	7/1/2026	N-PA19
Injectable Drugs	J9232	Injection, docetaxel (Hospira), not therapeutically equivalent to J9171, 1 mg	7/1/2026	N-PA19
Injection & Infusion Services	M0231	Intravenous infusion, tocilizumab-bavi, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)	7/1/2026	Yes
Injection & Infusion Services	M0232	Intravenous infusion, tocilizumab-bavi, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)	7/1/2026	Yes
Injectable Drugs	Q0234	Injection, tocilizumab-bavi, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5164	Injection, ustekinumab-hmny (Starjemza), biosimilar, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5165	Injection, denosumab-mobz (Oziltus), biosimilar, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5166	Injection, denosumab-desu (Osvyrti/Jubereq), biosimilar, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5167	Injection, denosumab-qbde (Enoby/Xtrenbo), biosimilar, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5168	Injection, ranibizumab-leyk (Nufymco), biosimilar, 0.1 mg	7/1/2026	Yes
Injectable Drugs	Q5169	Injection, pegfilgrastim-unne (Armlupeg), biosimilar, 0.5 mg	7/1/2026	Yes
Injectable Drugs	Q5170	Injection, aflibercept-boav (Eydenzelt), biosimilar, 1 mg	7/1/2026	Yes
Injectable Drugs	Q5171	Injection, denosumab-mobz (Boncresa), biosimilar, 1 mg	7/1/2026	Yes

Prior Authorization Requirement Updates

Prior Authorization requirements are applicable to participating and non-participating providers. Noncontracted Laboratories must obtain authorization for all services rendered.

For medications covered under the medical benefit that require authorization, providers are encouraged to submit authorization requests using the Blue Cross Complete Medication Prior Authorization Request form, which is available at mibluecrosscomplete.com. The completed form must be faxed to PerformRx at 1-855-811-9326.

Note: An authorization does not guarantee payment.